Wangler Michael F, Chao Yu-Hsin, Roth Mary, Welti Ruth, McNew James A
bioRxiv. 2024 Apr 29:2024.04.26.591192. doi: 10.1101/2024.04.26.591192.
Peroxisomal Biogenesis Disorders Zellweger Spectrum (PBD-ZSD) disorders are a group of autosomal recessive defects in peroxisome formation that produce a multi-systemic disease presenting at birth or in childhood. Well documented clinical biomarkers such as elevated very long chain fatty acids (VLCFA) are key biochemical diagnostic findings in these conditions. Additional, secondary biochemical alterations such as elevated very long chain lysophosphatidylcholines are allowing newborn screening for peroxisomal disease. In addition, a more widespread impact on metabolism and lipids is increasingly being documented by metabolomic and lipidomic studies. Here we utilize models of and as well as human plasma from individuals with mutations. We identify phospholipid abnormalities in larvae and brain characterized by differences in the quantities of phosphatidylcholine (PC) and phosphatidylethanolamines (PE) with long chain lengths and reduced levels of intermediate chain lengths. For diacylglycerol (DAG) the precursor of PE and PC through the Kennedy pathway, the intermediate chain lengths are increased suggesting an imbalance between DAGs and PE and PC that suggests the two acyl chain pools are not in equilibrium. Altered acyl chain lengths are also observed in PE ceramides in the fly models. Interestingly, plasma from human subjects exhibit phospholipid alterations similar to the fly model. Moreover, human plasma shows reduced levels of sphingomyelin with 18 and 22 carbon lengths but normal levels of C24. Our results suggest that peroxisomal biogenesis defects alter shuttling of the acyl chains of multiple phospholipid and ceramide lipid classes, whereas DAG species with intermediate fatty acids are more abundant. These data suggest an imbalance between synthesis of PC and PE through the Kennedy pathway and remodeling of existing PC and PE through the Lands cycle. This imbalance is likely due to overabundance of very long and long acyl chains in PBD and a subsequent imbalance due to substrate channeling effects. Given the fundamental role of phospholipid and sphingolipids in nervous system functions, these observations suggest PBD-ZSD are diseases characterized by widespread cell membrane lipid abnormalities.
过氧化物酶体生物发生障碍泽尔韦格谱系病(PBD-ZSD)是一组过氧化物酶体形成的常染色体隐性缺陷疾病,会导致出生时或儿童期出现多系统疾病。有充分记录的临床生物标志物,如超长链脂肪酸(VLCFA)升高,是这些病症的关键生化诊断结果。此外,诸如超长链溶血磷脂酰胆碱升高之类的继发性生化改变使得能够对过氧化物酶体疾病进行新生儿筛查。此外,代谢组学和脂质组学研究越来越多地记录了对代谢和脂质更广泛的影响。在这里,我们利用[具体模型名称1]和[具体模型名称2]模型以及来自患有[具体基因突变名称]突变个体的人血浆。我们在[具体生物名称1]幼虫和大脑中鉴定出磷脂异常,其特征在于长链长度的磷脂酰胆碱(PC)和磷脂酰乙醇胺(PE)数量存在差异,而中间链长度的水平降低。对于通过肯尼迪途径作为PE和PC前体的二酰基甘油(DAG),中间链长度增加,这表明DAG与PE和PC之间存在失衡,这表明两个酰基链库不平衡。在果蝇模型的PE神经酰胺中也观察到酰基链长度改变。有趣的是,人类受试者的血浆表现出与果蝇模型相似的磷脂改变。此外,人类血浆中碳链长度为18和22的鞘磷脂水平降低,但C24水平正常。我们的结果表明,过氧化物酶体生物发生缺陷会改变多种磷脂和神经酰胺脂质类别的酰基链穿梭,而具有中间脂肪酸的DAG种类更为丰富。这些数据表明,通过肯尼迪途径合成PC和PE与通过兰兹循环重塑现有PC和PE之间存在失衡。这种失衡可能是由于PBD中非常长和长酰基链过多以及随后由于底物通道效应导致的失衡。鉴于磷脂和鞘脂在神经系统功能中的基本作用,这些观察结果表明PBD-ZSD是以广泛的细胞膜脂质异常为特征的疾病。